HOW TO USE THIS BOOK
The Clinical Handbook of Psychotropic Drugs uses color coding and icons for intuitive navigation: -Blue sections contain general information on drugs / treatments and their availability. -Green sections cover drug action and dosing.
-Red sections outline warnings and precautions.
-Orange sections detail patient-and care-related information, such as nursing considerations and patient advice.
Below is a summary of the colors and icons used. 
General Information / Availability

Use in Pregnancy £
INTRODUCTION
The Clinical Handbook of Psychotropic Drugs for Children and Adolescents is intended to be a user-friendly and practical resource guide on the use of psychotropic drugs in children and adolescents. Its content is derived from various forms of published literature (including randomized controlled trials, scientišc data such as pharmacokinetic trials, cohort trials, case series, and case reports) as well as from leading clinical experts. We endeavor to continually update this handbook as the psychiatric literature evolves so we can continue to provide evidence-based clinically relevant information that is easily accessed and utilized to aid with patient care decisions. New sections, periodically added, re¦ect changes in therapy and in current practice.
Many classes of psychotropic drugs are used to treat childhood and adolescent mental illness on the basis of e³cacy in adults, despite not being currently approved for use in these populations. The lack of approval does not necessarily re¦ect lack of safety or e³cacy, but it does re¦ect a lack of controlled studies in these age groups. Many product monographs include a statement stating their drug has not been adequately studied in children and the safety of the drug has not been established under a specišc age.
In the Product Availability section of each chapter, the Clinical Handbook includes monograph statements regarding the recommendations for the use of each drug in children and adolescents. Approved indications for children and adolescents are stated, as are those for adults; also included are nonapproved indications for these drugs. Each chapter includes data from open and double-blind studies, where available, regarding doses, adverse e−ects, and other considerations in children and adolescents.
Because of a lack of comparative data in children and adolescents for most drug classes, Adverse Reaction tables and Drug Interaction charts re¦ect information that pertains to heterogeneous age groups (youth and adults).
Patient and Caregiver Information Sheets for most drug categories are provided as printable pdf šles to facilitate education/counselling of patients receiving these medications and their caregivers. For details, please see p. 354.
Most children and adolescents with a diagnosable psychiatric disorder require multimodal interventions to address the symptoms of the disorder, the comorbid conditions, and the psychological, social, and developmental sequelae. Individual and family psychoeducation are essential, and psychosocial interventions should be considered for most psychiatric disorders.
Until systematic double-blind studies of various psychotropic drugs have been conducted to determine the e³cacy, the pharmacokinetics, as well as the relative and absolute risks of each drug in this population, physicians who choose to use specišc psychotropic drugs in children and adolescents should review all available studies and monitor their patients on a regular basis. Consideration should be given to obtaining informed consent from the caregiver or youth (depending on the patient's age) for use in unapproved indications.
Given that changes may occur in a medication's indications, and di−erences are seen among countries, specišc "indications" listed in this text as "approved" should be viewed in conjunction with product monographs approved in your jurisdiction of interest. Dose comparisons and plasma levels are based on scientišc data. However, it is important to note that some patients will respond to doses outside the reported ranges. Age, sex, and the medical condition of the patient must always be taken into consideration when prescribing any psychotropic agent.
The purpose of this handbook is to provide quick access to relevant, practical, and important information clinicians should be aware of when considering pharmacological options available in the treatment of childhood and adolescent psychiatric disorders. It provides an overview of the plausible alternatives, dosing guidelines, as well as information on drug interactions and potential side e−ects. It is meant to be a resource to both those in training and experienced clinicians.
For those who like the convenience of electronic resources, the Clinical Handbook of Psychotropic Drugs for Children and Adolescents is also available as an online version that provides even quicker access to all the information in the handbook, with some added extras: (1) An auto-completion powered search function, (2) browse features for generic names, trade names, indications, and interacting agents, (3) column-selector enhancement of comparison charts (dosages, side e−ects, pharmacokinetics, interactions. . . ) that allows you to choose which information is displayed, and (4) hundreds of additional references. Further details on this can be found at http://www.hogrefe.com/chpd-online Over the years, many readers have asked many interesting questions and provided useful comments and suggestions regarding the content and format of the handbook. This input is critical to keeping this handbook current, accurate, and relevant to the readership. We really appreciate the feedback. Please feel free to e-mail me at the address below with your comments and questions. 
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PSYCHIATRIC DISORDERS IN CHILDREN AND ADOLESCENTS
Signišcant psychiatric illnesses a−ect approximately 10-15% of North American children and adolescents. These consist of conditions such as mood and anxiety disorders, bipolar disorder, attention-dešcit/hyperactivity disorder (ADHD), schizophrenia, Tourette's disorder, and autism spectrum disorder. Symptoms of these disorders are often serious and have an enormous impact on the lives of the patients and their families. Many factors complicate the recognition, management, and treatment of psychiatric disorders in children and adolescents. These include a high variance in symptom presentation and interpretation, diagnostic di³culties, scarcity of resources, research limitations, environmental in¦uences, societal attitudes, and medication issues. In a signišcant change, DSM-5 (released 2013) [1] removed the category of disorders usually šrst diagnosed in infancy, childhood, or adolescence. Where applicable, diagnostic considerations specišc to presentation of a disorder in infancy, childhood, or adolescence are included with each disorder. This chapter covers the following diagnoses:
ADHD is a heterogeneous behavioral disorder šrst evident in children before the age of 12
Prevalence
• There is no evidence to suggest that ADHD prevalence is increasing when standardized diagnostic procedures are followed [2] • 3-7% (4-12% in the USA)
Onset
• Symptoms begin as early as age 3; several inattentive or hyperactive-impulsive symptoms must be present by age 12 • 3-6 times more common in male than female children (but may be underreported in females); some individuals with inattentive presentation may mask symptoms by being quiet
Risk Factors
• 
Course of Illness
• Hyperactive-impulsive behaviors tend to diminish as the person ages; inattention and restlessness often continue • About 70% of children who are diagnosed with ADHD continue to have some symptoms in mid-adolescence and for about 40% this continues into adulthood
Consequences of ADHD
• Can result in poor academic performance, self-esteem, social and interpersonal relationships • High risk of injuries (4 times that of non-a−ected individuals) and 50% more likely to have a motor vehicle accident than non-a−ected individuals [3] • If inadequately treated, these children and adolescents are at increased risk for abusing substances (50% vs. 30% in non-a−ected individuals) and developing antisocial personality disorder • Educational and employment di³culties, problems with driving and with sexual relationships • Risk of teen pregnancy is 50% (vs. 4% in non-a−ected individuals) • 20% risk of incarceration (vs. 1% in non-a−ected individuals) • Minor involuntary movements (tics) occur in 8-11% of school-age children with ADHD
Treatment
• Treatment did not a−ect prognosis in a large longitudinal study (MTA) [4] , so collaborative, multimodal approaches, including psychoeducation, pharmacotherapy (stimulants, atomoxetine, α 2 agonists, selected antidepressants), and behavioral interventions are recommended and ongoing monitoring is necessary • See chapters on Drugs for ADHD (pp. 22-41) and Antidepressants (pp. 44-109)
Major Depressive Disorder (MDD)
Major depressive disorder is a mood disorder with signišcant physical and mental symptoms that causes signišcant impairment in a child's functioning • Ensure dosage prescribed is therapeutic and attempt to have peak serum levels occur at those times of the day that symptoms are most prominent • Consider trying a stimulant from an alternate class (methylphenidate or amphetamine) if the šrst trial was ine−ective and the patient was adhering to therapy recommendations
Prevalence
Factors Complicating Response
• Concurrent medical or psychiatric condition, e.g., bipolar disorder, conduct disorder, learning disability • Concurrent prescription drugs may interfere with e³cacy, e.g., antipsychotics (see Drug Interactions pp. 29-30, 33, 40)
• Metabolic inducers (e.g., carbamazepine) may decrease the plasma level of methylphenidate • High intake of acidifying agents (e.g., fruit juices, vitamin C) may decrease the e³cacy of amphetamine preparations • Substance use, including alcohol and marijuana, may make management di³cult; need to discontinue substance use to optimize treatment outcomes • Side e−ects to medication • Psychosocial factors may a−ect response; nonpharmacological treatment approaches (e.g., behavior modišcation, psychotherapy, and education)
can increase the probability of response
Augmentation Strategies
Methylphenidate/ Dexmethylphenidate/ Dextroamphetamine + α 2 agonist
• Additive e−ect on hyperactivity, aggression, mood lability, and sleep problems; studies indicate e³cacy in 50-80% of patients. Has been found helpful in patients with concomitant tic disorders, conduct disorder or oppositional dešant disorder [monitor ECG, heart rate, and blood pressure with combination] • Kapvay (clonidine XR) and Intuniv (guanfacine XR) are approved for adjunctive use with stimulant medications
Psychostimulants + Antidepressants
• Tricyclics (imipramine, nortriptyline, and desipramine) useful in refractory patients or those with concomitant enuresis or bulimia; they may reduce abnormal movements in patients with tic disorders. There is an increase in the incidence of adverse e−ects, including cardiovascular, GI, anticholinergic e−ects, and weight gain; use caution and limit quantities prescribed in patients at risk of overdose • SSRIs or venlafaxine may be e−ective in adult patients with concomitant mood or anxiety disorders (e.g., PTSD) • Bupropion used to augment e−ects of psychostimulants and in patients with concomitant mood disorder, substance use disorder, or conduct disorder. May cause dermatological reactions, exacerbate tics, and increase seizure risk
Psychostimulants + Atomoxetine
• Use in patients who have partial relief of symptoms with maximally tolerated doses of stimulants alone. The combination may permit lower stimulant doses and allows robust coverage as well as coverage early and late in the day and in the summer • Monitor for increased blood pressure, tachycardia, and weight loss
Psychostimulants + Antipsychotics
• Second-generation antipsychotics (low doses of risperidone, aripiprazole or quetiapine) may be useful in patients with comorbid symptoms of dyscontrol, aggression, hyperactivity, and tics. Ensure appropriate metabolic monitoring of antipsychotic therapy completed and discontinue antipsychotic treatment if excessive BP, weight, cholesterol, triglyceride or glucose tolerance occur • Low doses of haloperidol, risperidone, and pimozide have been used in patients with concurrent Tourette's disorder
Psychostimulants + Mood Stabilizers
• Combination used in patients with comorbid bipolar disorder, conduct disorder, impulsivity, and aggression; infrequent case reports in children include the use of lithium, carbamazepine , and valproate -the possibility of drug interactions should be considered (see Drug Interactions pp. 
General Comments
• Some antidepressants are associated with restlessness or psychomotor agitation prior to seeing any change in core symptoms of depression. Antidepressants are also associated with a small (2-3%) risk of hostility or suicidal ideation and associated behaviors in children, adolescents, and young adults (aged up to 24 years). Risk for suicide should be closely assessed and monitored during the initial weeks of antidepressant therapy In patients with major depression and a high risk of suicide, treatment selection should consider safety in overdose (i.e., consider using newer antidepressant agents rather than nonselective cyclic and MAOI antidepressants) and close monitoring • Two recent studies examining previously published RCTs of ¦uoxetine and venlafaxine have shed some doubt on the validity of some of the black box warnings issued on antidepressants in 2004-2006 for risks of increasing suicidal ideation. [1, 2] Hence, there still appears to be some uncertainty, despite a well conducted meta-analysis and review by the FDA • Use of antidepressants in children with bipolar disorder (with mixed features) reported to cause increased cycling (in 79%), increased aggression (71%), and increased psychotic symptoms (23%) when not using a mood stabilizer • Though some randomized double-blind, controlled trials and systematic reviews suggest otherwise, on average, all antidepressants are equally e³cacious at reducing symptoms of depression. Overall e−ects of antidepressants are modest when the e−ects of publication bias are considered. Compared to placebo, the overall e−ect size of treatment is reported as being 0.31
• On the basis of some RCTs [4] and the TADS trial [5, 6] it has been suggested that ¦uoxetine may o−er a more favorable benešt-to-risk ratio in pediatric depression, despite the fact that only some of the clinician-rated measures indicated a di−erence favoring ¦uoxetine • A meta-analysis of "new generation" antidepressants found escitalopram and sertraline to have better e³cacy or acceptability for treating MDD in adults [7] • Di−erent antidepressant classes may be combined in patients with a partial response or in refractory cases; however, consideration of, and additional monitoring for, the potential interactions such as serotonin syndrome is necessary • Prophylaxis of depression is most e−ective if the therapeutic dose is maintained; continued therapy with all classes of antidepressants has been shown to signišcantly reduce risk of relapse
• Epidemiological studies of various designs have reported that antidepressant prescribing has declined following the 2004 increased suicidality warnings, however, other studies examining prescribing data from 1998 to 2007 suggest that prescription rates of antidepressants have not decreased despite the warnings [8] • The Treatment of Adolescent Suicide Attempters study, examined SSRI treatment, cognitive-behavioral therapy (CBT) plus suicide prevention, or a combination in 124 adolescents with moderate to severe depressive symptoms who had previously attempted suicide. After six months of treatment, 22% taking an SSRI had a suicide-related event compared with 6.7% not on a SSRI [9] • Tolerance (tachyphylaxis or "poop-out" syndrome) has been reported in 10-20% of patients on various antidepressants, despite adherence to therapy. Possible explanations include adaptations in the CNS, increase in disease severity or pathogenesis, loss of placebo e−ect, unrecognized rapid-cycling, incorrect diagnosis, comorbid substance use, anxiety disorders, ADHD or eating disorders. [Check compliance with therapy; dosage adjustment may help; switching to an alternate antidepressant (p. 107) or augmentation strategies (p. 109) have also been tried] • A 2013 systematic review in depressed and anxious youths taking antidepressants demonstrated that the overall rate of activation-related or arousal adverse events of treated youths was 3-10 times higher than for those assigned to placebo. [10] Given the connection suggested between the arousal adverse events and potential for suicidality, this šnding supports recommendations for close monitoring for arousal, agitation, and risk for suicidality when youths are prescribed antidepressants
Therapeutic Effects
• Elevation of mood, improved appetite and sleep patterns, increased physical activity, improved clarity of thinking, better memory; decreased feelings of guilt, worthlessness, helplessness, inadequacy, decrease in delusional preoccupation and ambivalence Oral solution: 20 mg/mL (B) Approved in the USA for children age 6 and above (A) Generic preparations may be available, (B) Not marketed in Canada, (C) Not marketed in the USA Indications ‡ ( approved) In children and adolescents: Depression (age 8 and above: ¦uoxetine -USA; age 12 and above: escitalopram -USA) Bipolar depression (age 10 and above: ¦uoxetine/olanzapine combination -USA) Obsessive-compulsive disorder (OCD) (USA: sertraline -age 6 and above, ¦uoxetine -age 7 and above, ¦uvoxamine -age 8 and above) USA) • No SSRIs are approved for use in children and adolescents in Canada • SSRIs have been used in the treatment of depression, dysthymia, social anxiety disorder, anxiety, panic disorder, bulimia, OCD, Tourette's disorder, and ADHD; preliminary data suggest e³cacy in some children with autism spectrum disorder and selective mutism 
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Psychotropic Drugs
This book is designed to fill a need for a comprehensive but compact and easy-to-use reference for all mental health professio nals dealing with children and adolescents. This new edition of the widely praised Clinical Handbook summarizes the latest information from the published literature (monograph statements, scientific data, controlled clinical trials, case reports) and clinical experience in compact and easy-to-use charts and bulleted lists for each class of psychotropic drugs used in children and adolescents. This 3rd completely revised and expanded edition of the highly acclaimed psychotropic drug reference for all health care professionals dealing with children and adolescents is now more user friendly than ever:
Updated information on psychiatric disorders in children and adolescents (including DSM-V changes)
Packed with unique comparison charts (dosages, side effects, pharmacokinetics, interactions…) that allow you to see at a glance which medication is the most suitable for each patient Now in full color throughout and with instantly recognizable icons that allow you to find at a glance all the information you seek: -General information on medications, availability, and indications -Drug action, dosing, pharmacokinetics, and related areas -Warnings and precautions -Patient-related information, such as lab monitoring recommendations, nursing implications, and patient advice
